BMS acquired an exclusive option to purchase Promedior and worldwide rights to PRM-151 for $150M upfront with up to $1.1B in additional payments tied to the option exercise and clinical/regulatory milestones. BMS allowed the option to expire in 2019 without exercise. Promedior was later acquired by Roche for ~$1.4B in 2020.